Engineered measles virus as a novel oncolytic therapy against prostate cancer

Prostate

Volumn 69, Issue 1, 2009, Pages 82-91

  Msaouel, Pavlos ^a,b   Iankov, Ianko D ^a   Allen, Cory ^a   Morris, John C ^a   Von Messling, Veronika ^c   Cattaneo, Roberto ^a   Koutsilieris, Michael ^b   Russell, Stephen J ^a   Galanis, Evanthia ^a,d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITÉ LAVAL   (Canada)

^d NONE   (United States)

Author keywords

CEA; Measles virus; MV CEA; Prostate cancer; Virotherapy

Indexed keywords

CANCER VACCINE; GREEN FLUORESCENT PROTEIN; MEASLES VIRUS PLUS CARCINOEMBRYONIC ANTIGEN; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; CD46 PROTEIN, HUMAN; HYBRID PROTEIN; LUCIFERASE; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL STRAIN; CELL STRAIN LNCAP; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR KILLING; MALE; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SUPERNATANT; SURVIVAL TIME; VIROGENESIS; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; DRUG SCREENING; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; VERO CELL;

ANIMALS; ANTIGENS, CD46; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FLOW CYTOMETRY; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; LUCIFERASES; MALE; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149345608     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20857     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71 -96.
2. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165(1):119-125.
3. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999;281(17):1598-1604.
4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148(6):435-448.
5. Patel P, Ashdown D, James N. Is gene therapy the answer for prostate cancer? Prostate Cancer Prostatic Dis 2004;7(Suppl 1) S14-S19.
6. Wild TF, Malvoisin E, Buckland R. Measles virus: Both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol 1991;72(Pt 2):439-442.
7. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. j Virol 1993;67(10):6025-6032.
8. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75(2):295-305.
9. Cattaneo R. Four viruses, two bacteria, and one receptor: Membrane cofactor protein (CD46) as pathogenś magnet. J Virol 2004;78(9):4385- 4388.
10. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406(6798):893-897.
11. Cutts FT, Markowitz LE. Successes and failures in measles control. J Infect Dis 1994;170(Suppl 1) S32-S41.
12. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64(14):4919-4926.
13. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: Basal and induced mechanisms. Mol Immunol 1999;36 (13-14):929-939.
14. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40(2-4):109-123.
15. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63(10):2462-2469.
16. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002;62(16):4656-4662.
17. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (Baltimore, MD) 2006;44(6):1465-1477.
18. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103(5):1641-1646.
19. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97(12):3746-3754.
20. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98(7):2002-2007.
21. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev 2008;6(7):529-540.
22. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002;8(5):527-531.
23. Radecke F, SpielhoferP, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA. Rescue of measles viruses from cloned DNA. EMBO J 1995;14(23):5773-5784.
24. Duprex WP, McQuaid S, Roscic-Mrkic B, Cattaneo R, McCallister C, Rima BK. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 2000;74(17):7972-7979.
25. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006;99(2):177-184.
26. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 2007;5(8):823-832.
27. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000;60(13):3429-3434.
28. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membranebound complement regulatory proteins in prostate cancer. Urology 2005;66(6):1321-1326.
29. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20(12):576-582.
30. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 2005; 173(2): 342-359.
31. Mrkic B, Odermatt B, Klein MA, Billeter MA, Pavlovic J, Cattaneo R. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol 2000;74(3):1364-1372.
32. Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998;72(9): 7420-7427.
33. Roscic-Mrkic B, Schwendener RA, Odermatt B, Zuniga A, Pavlovic J, Billeter MA, Cattaneo R. Roles of macrophages in measles virus infection of genetically modified mice. J Virol 2001;75(7):3343-3351.
34. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther2003;14(16): 1565-1577.
35. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008;8(2):213-220.
36. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82(6):700-710.
37. Neufeld L, Dubin A, Guinan P, Nabong R, Ablin RJ, Bush IM. Carcinoembryonic antigen in the diagnosis of prostate carcinoma. Oncology 1974;29(5):376-381.
38. Heinzerling L, Kunzi V, Oberholzer PA, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005;106(7):2287-2294.
39. Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska JP, Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). J Clin Oncol 2008; 26(15s):302s.
40. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ. Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15(1):114-122.
41. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14(4): 324-333.
42. Munguia A, Ota T, Miest T, Russell SJ. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 2008;15(10):797-806.
43. Ibid. SR